Skip to main content
OpenTrials
Completed

NCT Number: NCT00555750

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in the United States as LUNESTA.

Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that can be reversed by two months of eszopiclone for the primary insomnia

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brigham and Women's Hospital, Division of Sleep Medicine

Boston, Massachusetts, 02115, United States

About this study

Insomnia is the most common sleep disorder, affecting nearly one-third of all adults in any given year, and chronically affecting 10-15% of the adult population. Reduced sleep time, independent of insomnia, has been associated with a variety of deleterious long term effects, including an increased risk of incident myocardial infarction and symptomatic diabetes. Chronic partial sleep loss or insomnia may impair glucose metabolism in the short term and are associated with the development of diabetes in the long term. Although the extent of sleep loss is more acute in the laboratory-based 'sleep debt' studies of healthy volunteers, chronic primary insomnia patients exhibit 'hyperarousal' (hypercortisolemia in the afternoon and evening, accelerated metabolism) similar to that seen with acute sleep deprivation. In addition, degradations of sleep quantity and quality in primary insomnia have been attributed to cognitive and somatic hyperarousal in the sleep setting. study examines and quantifies in adult men and women the link between primary insomnia and impaired glucose tolerance. This study examines the extent which adequate treatment of primary insomnia reverses impairments of glucose metabolism. If abnormalities of glucose metabolism are reversible, this study will demonstrate the importance of treatment of chronic primary insomnia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 25-55
  • Complaint of insomnia of at least 6 months duration
  • DSM-IV diagnosis of Primary Insomnia
  • Sleep diary: mean Total Sleep Time < 6 hours and a mean total wake time (sleep latency + wake after sleep onset) of greater than 60 minutes (in previous 14 days as recorded on sleep diary)
  • A willingness to comply with study procedures
  • If of child-bearing potential, using a medically-accepted method of birth control, including abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method, and intrauterine device [IUD])

Exclusion criteria

  • Current diagnosis of DSM-IV Axis I disorder other than Primary Insomnia
  • Regular treatment (more than 1 time/week) with CNS active medication within 1 month of fist inpatient visit
  • Treatment with medications that interfere with glucose metabolism including anti-diabetic medications or steroidal contraceptives
  • Uncontrolled medical illness that would interfere with participation in the study
  • Body Mass Index >32 or <19.8
  • Current symptoms or diagnosis of any moderate to severe sleep disorder other than insomnia
  • No menopausal or peri-menopausal symptoms that disrupt sleep
  • Pregnant, lactating or planning to become pregnant
  • Consumption of > 2 caffeinated beverages per day (including coffee, tea and/or other caffeine-containing beverages or food) during 3 weeks prior to the start of the study

Treatment and study plan

Eszopiclone

Drug

3mg tablet, by mouth nightly 30 min before bed, for two months

Other names: Lunesta

Placebo

Drug

inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months

Primary outcomes

  1. Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test

    Time frame: baseline and 2 months post-treatment

    Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.

Secondary outcomes

  1. Acute Insulin Response to Glucose (AIRg)

    Time frame: baseline and 2 months post-treatment

    Change over two months in 1st phase Insulin secretion

  2. Change in Insulin Sensitivity (SI)

    Time frame: baseline and 2 months post-treatment

    Insulin sensitivity index (SI) "was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma." [R. Bergman, Horm Res 2005;64(suppl 3):8-15].

    SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)

  3. Change in Glucose Effectiveness (SG)

    Time frame: baseline and 2 months post-treatment

    Glucose effectiveness was defined as "the ability of glucose itself to enhance its own disappearance independent of an increment in insulin." [R. Bergman, Horm Res 2005;64(suppl 3):8-15].

    SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)

  4. Change in HbA1c Levels

    Time frame: baseline and 2 months post-treatment

    Difference in HbA1c levels following two months treatment with eszopiclone versus placebo

  5. Pre-Treatment Leptin Levels

    Time frame: baseline

    Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast

  6. Post-treatment Leptin Levels

    Time frame: two months post-treatment

    Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast

  7. Pre-treatment Ghrelin Levels

    Time frame: baseline

    Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast

  8. Post-treatment Ghrelin Levels

    Time frame: 2 months post-treatment

    Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast

  9. Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)

    Time frame: baseline and 2 months post-treatment

    At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 ("very alert") to 9 ("very sleepy, fighting sleep, an effort to keep awake"). Subjective sleepiness was defined as mean deviation from baseline KSS.

  10. Change in Mean Lapses of Attention

    Time frame: baseline and 2 months post-treatment

    At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.

  11. Change in Total Sleep Time as Reported in Sleep Diaries

    Time frame: baseline and 2 months post-treatment

    Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).

  12. Change in Total Sleep Time Measured by PSG

    Time frame: baseline and 2 months post-treatment

    Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Mclean Hospital
  • National Center for Research Resources (NCRR)
  • Sumitomo Pharma America, Inc.

Registry information

Official study title

The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Nov 9, 2007
Registry last updated
Dec 10, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.